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The 2019 novel coronavirus (the cause of COVID-19) 
was announced as a global pandemic by the World 
Health Organization on 11th March 2020 (1). COVID-
19 viral pneumonia is caused by a Severe Acute 
Respiratory Syndrome coronavirus 2 (SARS-CoV-2), 
following the rapid outbreak from Wuhan, China, to all 
other parts of the world (2). This virus is the third 
member of the human coronavirus family which leads 
to acute respiratory distress syndrome (ARDS) after 
the SARS-CoV in 2003 and the Middle East 
respiratory syndrome coronavirus (MERS-CoV) in 
2012 (3). It seems that these highly contagious 
coronaviruses use the same immune-pathology 
mechanism linked to ARDS, originated from an 
excessive immune response, also called a “cytokine 
storm syndrome” (4). This toxic immune overreaction 
is a type of systemic inflammatory response due to the 
marked release of various pro-inflammatory cytokines 
and chemokines by immune effector cells (5). 
Although the cytokine storm secretion profile in 
COVID-19 disease is generally similar to SARS-CoV and 
MERS-CoV infections, some critical differences existed, 
especially on the levels of T-helper-2 (Th2) cytokines 
concentrations (6). It has been observed that the levels of 
Pro-inflammatory cytokines such as interleukin 1β (IL-
1β), interferon γ (IFN-γ), interferon-inducible protein 10 
(IP-10), and monocyte chemoattractant protein 1 (MCP-
1) are increased in patients with 2019-nCoV, SARS-CoV 
and MERS-CoV infections (6, 7). However, SARS-CoV-
2 infection is different from other coronaviruses in terms 
of various concentrations of Th2 cytokines. IL-4 and IL-
10 are key cytokines of Th-2 lymphocytes and has 
immune regulatory functions through the inhibition of 
Th-1 cytokine secretion (7). IL-4 could trigger a 
secondary hemophagocytic lymphohistiocytosis (HLH). 
HLH is a kind of cytokine storm syndrome in-dependent 
on T cells or IFN-γ (8). 
Also, elevated serum concentrations levels of 
some Th2 cytokines such as IL-4 were detected in 
individuals with SARS-CoV-2 whereas, the levels of IL-
4 in subjects of MERS or SARS patients showed a 
decrease (2). Thus, it can be one of the noteworthy 
differences between cytokines profiles in the 
pathogenesis of COVID-19 infections compared to SARS 
and MERS coronavirus. 
It is well-known that the over-production of Th-2 
cytokines could result in chronic inflammatory diseases 
including atopic dermatitis (AD), asthma, and allergic 
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rhinitis (9). Dupilumab is a fully human monoclonal 
antibody that inhibits the signaling pathway of the 
common receptors of IL-4 and IL-13. Dupilumab can 
control the AD inflammatory disease with a favorable 
safety profile (10). It is considered that it does not 
augment the risk of viral infections (11). According to the 
increased level of IL-4 in the COVID-19 pandemic, the 
suppression of elevated IL-4 probably could be an ideal 
immuno-modulating option.  
Recently, Ferrucci et al reported the dupilumab 
therapy course in two patients who had concurrently AD 
and Covid-19 infection. Both patients had been 
undergone dupilumab treatment a few months before 
being infected with COVID-19. Furthermore, the 
patients’ first-degree relatives (father of one patient and 
the husband of another one) were also affected with 
COVID-19, too. Interestingly, both of the patients 
developed a mild form of COVID-19 disease and showed 
a progressive improvement in the clinical symptoms, 
while their infected first-degree relations died for 
interstitial pneumonia (12). More interestingly, the same 
authors enrolled 245 patients with COVID-19 infection in 
Milan, Italy, a geographic area with a high incidence of 
Covid-19, in a trial using dupilumab therapy. They found 
that only 2 patients (0.82%) progressed COVID-19 
infection and eventually none had serious sequels of the 
disease. Suggestively, they approved that dupilumab was 
an effective and safe treatment option for individuals with 
systemic inflammatory response associated infections 
(12). 
In conclusion, according to the above-mentioned 
evidence, IL-4 functions differ in various coronavirus 
infections. Due to the high morbidity and mortality rate 
associated with the COVID-19 infections, the increased 
serum levels of IL-4 may exacerbate pathological 
conditions, however, the consequence of elevated IL-4 
levels in the infected people needs much more attenuation 
and more clinical trials are required to confirm the 
positive outcomes of IL-4 inhibition in SARS-CoV-2 
infected individuals with elevated IL-4. 
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